Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Fineline Cube May 8, 2026
Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Fineline Cube May 8, 2026
Company Deals Drug

Grifols Partners with BARDA to Develop Treatment for Sulfur Mustard Ocular Injury

Fineline Cube Oct 23, 2024

Grifols (BME: GRF; NASDAQ: GRFS), a Spanish biopharmaceutical company, has announced a partnership with the...

Policy / Regulatory

Hunan Province Launches Pilot Program for Retail Sales of VBP Drugs with Strict Guidelines

Fineline Cube Oct 23, 2024

The Hunan Healthcare Security Administration has released the “Pilot Implementation Plan for Volume-based Procurement (VBP)...

Company Drug

Walvax Biotechnology’s Weuphoria Vaccine Approved in Oman for Pediatric Pneumococcal Infections

Fineline Cube Oct 23, 2024

Walvax Biotechnology Co., Ltd (SHE: 300142), a Chinese biopharmaceutical company, has announced that it has...

Company Medical Device

German Endoscope Maker KARL STORZ Secures Marketing Approval for Disposable Ureteroscope in China

Fineline Cube Oct 23, 2024

KARL STORZ SE & Co. KG, a leading German endoscope manufacturer, has announced that it...

Company Drug

LENZ Therapeutics’ Presbyopia Therapy LNZ100 Accepted for FDA Review

Fineline Cube Oct 23, 2024

LENZ Therapeutics, Inc. (NASDAQ: LENZ), a US-based biopharmaceutical company, has announced that the US Food...

Company

Macrolux Raises Over RMB 100 Million in Series B Financing

Fineline Cube Oct 23, 2024

Macrolux, a leading medical technology company specializing in disposable endoscopes, has announced the completion of...

Company Drug

AstraZeneca’s Wainzua Earns CHMP Nod for hATTR-PN Treatment in the EU

Fineline Cube Oct 22, 2024

UK pharmaceutical juggernaut AstraZeneca (AZ, NASDAQ: AZN) has announced that Wainzua (eplontersen), an RNA-targeted therapy...

Company Drug

Novo Nordisk’s Semaglutide Shows 14% Reduction in Cardiovascular Events in Landmark SOUL Trial

Fineline Cube Oct 22, 2024

Copenhagen-based healthcare giant Novo Nordisk (NYSE: NVO) has declared the primary outcomes of the SOUL...

Company Medical Device

Thermo Fisher’s Oncomine Dx Target Test Gets FDA Green Light as Companion Diagnostic for Servier’s Voranigo

Fineline Cube Oct 22, 2024

US pharmaceutical and biotechnology company Thermo Fisher Scientific (NYSE: TMO) has received marketing approval from...

Company Deals

GSK and Cambridge University Forge £50 Million Partnership to Tackle Immune Diseases

Fineline Cube Oct 22, 2024

UK pharmaceutical giant GSK plc (LON: GSK, NYSE: GSK) has unveiled a significant five-year partnership...

Company Drug

AstraZeneca’s Saphnelo Approved for Use in Guangdong Under ‘Hong Kong-Macau Drug Access’ Policy

Fineline Cube Oct 22, 2024

AstraZeneca (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has announced that its drug Saphnelo...

Company Deals

InventisBio Acquires Immuno-Oncology Assets from Lyvgen Biopharma in RMB1.5 Million Deal

Fineline Cube Oct 22, 2024

InventisBio (Shanghai) Co., Ltd (SHA: 688382), a Chinese biotechnology company, has announced a transfer agreement...

Company Drug

BeiGene’s Tevimbra Receives CHMP Recommendation for Expanded Use in G/GEJ and ESCC Cancers in EU

Fineline Cube Oct 22, 2024

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading China-based biotechnology company, has received...

Company Drug

Olymvax Bio Receives NMPA Approval for Clinical Study of Trivalent Influenza Vaccine

Fineline Cube Oct 22, 2024

Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, has announced that...

Drug Medical Device Policy / Regulatory

Guangzhou Releases First Batch of Innovative Drugs and Medical Devices List, Featuring Local Companies

Fineline Cube Oct 22, 2024

The Guangzhou Municipal Industry and Information Technology Bureau has unveiled the first batch of innovative...

Company Drug

Sino Biopharmaceutical’s Anlotinib Receives Ninth Indication Approval from China’s CDE for Soft-Tissue Sarcoma

Fineline Cube Oct 22, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading pharmaceutical company in China, has announced that it...

Company

GenScript Dissolves Merger with CAR-T Specialist Legend Biotech, Reclassifies as Associated Company

Fineline Cube Oct 22, 2024

GenScript Biotech Corporation (HKG: 1548), a comprehensive life science research and application service and product...

Policy / Regulatory

China’s NMPA Greenlights Pilot Plan for Phased Manufacturing of Biological Products

Fineline Cube Oct 22, 2024

The National Medical Products Administration (NMPA) has given its stamp of approval to the “Pilot...

Company Deals

Otsuka Holdings Weighs Sale of Stake in Medical Device Maker MicroPort Scientific

Fineline Cube Oct 22, 2024

Otsuka Holdings Co., a Japanese pharmaceutical and healthcare company, is reportedly considering the sale of...

Company Deals Medical Device

Dongcheng Pharma Moves to Enhance Portfolio with Acquisition of Rongcheng Medical’s GSA Injection

Fineline Cube Oct 22, 2024

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has announced its intention to acquire...

Posts pagination

1 … 276 277 278 … 662

Recent updates

  • China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban
  • Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies
  • Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort
  • Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance
  • Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Company

Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.